Market Overview

UPDATE: Credit Suisse Initiates Regeneron Pharmaceutical at Outperform

Share:
Related REGN
The Market In 5 Minutes: Tax Overhaul In Focus As Senate Passes Budget Plan
Benzinga's Top Upgrades, Downgrades For October 20, 2017

Credit Suisse initiales coverage on Regeneron Pharmaceutical (NASDAQ: REGN) with an Outperform rating and a $187 price target.

Credit Suisse said, "The primary value driver remains quarterly sales of Eylea. Proposed legislation regulating compounding pharmacies, a permanent J code in January and the launch in RVO could all help boost sales. Competitor data for Amgen's AMG145 (anti-PCSK9) and Ophthotech's Fovista have all recently been disclosed, and key clinical data for Regeneron are limited in the near term."

Regeneron Pharmaceutical closed at $144.90 on Monday.

Latest Ratings for REGN

DateFirmActionFromTo
Oct 2017BarclaysDowngradesEqual-WeightUnderweight
Oct 2017Morgan StanleyMaintainsEqual-Weight
Sep 2017UBSMaintainsBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (REGN)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...